#USA #New York #Securities Fraud #Pomerantz LLP #Valneva SE

Pomerantz Law Firm Launches Investigation into Valneva SE

The Pomerantz Law Firm, known for its expertise in corporate law, has initiated an investigation into potential claims for investors of Valneva SE (NASDAQ: VALN). This inquiry centers on whether Valneva and its executive leadership may have engaged in fraudulent securities practices or other unlawful actions that could impact shareholders.

Background of the Investigation

On February 25, 2025, the U.S. Centers for Disease Control and Prevention (CDC) publicized a statement that led to considerable concern among Valneva's investors. The notice revealed that the CDC was investigating multiple cases of serious health issues, including cardiac and neurological events, following the administration of IXCHIQ, Valneva's chikungunya virus vaccine, to individuals aged 65 and over. Following this announcement, Valneva’s American Depositary Receipt (ADR) price fell dramatically, suffering a decline of $1.06, or 13.57%, within just four trading days, closing at $6.75 per ADR by February 28, 2025.

Subsequently, on August 22, 2025, another blow came when the U.S. Food and Drug Administration (FDA) suspended the marketing application for IXCHIQ due to safety concerns. This announcement resulted in an additional drop in the ADR price of $2.21, approximately 18.99%, closing at $9.43 on August 25, 2025. The rapid decline in share value has raised serious questions regarding the company’s communications and the integrity of its business practices.

Pomerantz’s Role

Founded by the influential attorney Abraham L. Pomerantz, Pomerantz LLP has built a reputation for its commitment to protecting investor rights and pursuing corporate ethics. The firm has successfully represented countless clients in cases of securities fraud and corporate misconduct, recovering significant awards for those affected. Their proactive approach aims to hold companies accountable for breaches of fiduciary duty and misconduct that harms shareholders. Interested investors are encouraged to reach out for guidance—Danielle Peyton can be contacted at [email protected] or 646-581-9980, ext. 7980.

Importance of Legal Action

Being part of a legal investigation, especially in complex financial matters, can be critical for investors who may have experienced losses. Pomerantz's investigation not only seeks to ascertain accountability but also aims to provide a pathway for those affected to seek redress for their financial injuries. With the firm's extensive history in class actions, its findings could potentially lead to collective legal action against Valneva, providing strength in numbers for investors pursuing claims.

Conclusion

As this situation unfolds, it underscores the importance for investors to remain vigilant regarding any business practices that may compromise their rights or investments. The allegations against Valneva SE and the subsequent actions taken by the Pomerantz Law Firm are a reminder of the ever-evolving landscape of corporate governance and investor protection. Stakeholders in Valneva are urged to stay informed and seek professional advice as needed. The consequences of these proceedings could extend beyond financial implications, impacting the company's reputation and future engagements within the biotechnology sector.